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The increasing adoption of left ventricular assist devices (LVADs) into clinical practice is
related to a combination of engineering advances in pump technology and improvements in
understanding the appropriate clinical use of these devices in the management of patients
with advanced heart failure. This review intends to assist the clinician in identifying
candidates for LVAD implantation, to examine long-term outcomes and provide an overview
of the common complications related to use of these devices.
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journal homepage: www.elsevier.com/locate/ihjThe increasing adoption of left ventricular assist devices
(LVADs) into clinical practice is related to a combination of
engineering advances in pump technology and improvements
in understanding the appropriate clinical use of these devices
in the management of patients with advanced heart failure.
This review intends to assist the clinician in identifying
candidates for LVAD implantation, to examine long-term
outcomes and provide an overview of the common complica-
tions related to use of these devices. In the early 1990s, larger
pulsatile LVADs (i.e. Novacor LVAD and Thoratec HeartMate
XVE) were initially used for left ventricular support in patients
awaiting cardiac transplantation. This strategy was not based
on randomized data but was adopted out of necessity, given
the long waiting times for cardiac transplantation.1 As
conﬁdence grew, the Randomized Evaluation of Mechanical* Corresponding author.
E-mail address: MMEHRA@BWH.HARVARD.EDU (M.R. Mehra).
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0019-4832/# 2016 Cardiological Society of India. Published by Elsevier
article under the CC BY-NC-ND license (http://creativecommons.org/lAssistance for the Treatment of Congestive Heart Failure
(REMATCH) trial was launched, which randomized 129
nontransplant candidates with end-stage heart failure to
ongoing medical therapy (72% of patients supported with
continuous intravenous inotropes) versus a pulsatile Heart-
Mate XVE and demonstrated a dramatic survival advantage at
one year (53% survival in the LVAD group and 25% survival in
the medical therapy group).2 This afﬁrmed the proof of concept
and viability of lifetime or destination therapy using mechan-
ical circulatory support (MCS) systems. The initial adoption of
pulsatile devices was low due to lesser device durability and
frequent morbidity, but as LVAD technology advanced, the
advent of smaller and more reliable continuous ﬂow devices
(HeartMate II LVAD and HeartWare HVAD) led to a dramatic
rise in utilization of LVADs in the past decade. In 2013, the, a division of Reed Elsevier India, Pvt. Ltd. This is an open access
icenses/by-nc-nd/4.0/).
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97% continuous ﬂow LVADs, 44% for destination therapy)
exceeded the number of cardiac transplants performed.3,4 For
the past decade, the number of cardiac transplants per annum
worldwide has remained stagnant at around 4000 related to
the relatively ﬁxed donor pool, with the vast majority of
cardiac transplants being performed in the United States and
Europe. Attempts at increasing the donor pool have been
outpaced by the improving clinical outcomes experience with
current generation LVADs contributing to a growing popula-
tion of transplant ineligible patients supported with these
devices as destination therapy. Balancing the risk–beneﬁt ratio
to match the device to the patient's condition will be
paramount in prolonging and improving life while achieving
cost-effectiveness.5
1. Patient selection
1.1. Selecting patients with the appropriate severity of
heart failure
Determining a level of severity of illness in patients with
advanced heart failure relies heavily on the degree of
symptoms, refractoriness to traditional disease modifying
therapy, and the worsening hemodynamic proﬁle. As ad-
vanced-stage heart failure sets in, the traditional New York
Heart Association classiﬁcation system is no longer sufﬁcient
to characterize patients. Thus, the Interagency Registry for
Mechanically Assisted Circulatory Support (INTERMACS)
proﬁle system assigns a level (INTERMACS level 1 through 7)
to patients based on the severity of illness (Table 1). Currently,
the majority of patients undergoing LVAD implantation are
either categorized as INTERMACS level 1 (critical cardiogenic
shock), level 2 (progressive decline on inotropic therapy), or
level 3 (stable but inotropic therapy dependent).3 INTERMACS
level 1 patients (those in critical cardiogenic shock) pose a
challenge to LVAD implantation. Speciﬁcally, there is an
increased risk of perioperative mortality (relative risk 1.55).6 In
response to the realization of the perioperative risk in patients
with cardiogenic shock, the proportion of patients undergoing
durable MCS implantation at INTERMACS level 1 hasTable 1 – Current distribution of durable mechanical
circulatory support devices across INTERMACS levels.
INTERMACS
Level
Deﬁnition % Of durable
MCS
1 Critical cardiogenic shock 14.3%
2 Progressive decline 36.0%
3 Stable but inotrope dependent 29.6%
4 Resting symptoms 14.5%
5 Exertion-intolerant 3.0%
6 Exertion-limited 1.2%
7 Advanced NYHA Class 3 0.7%
INTERMACS, Interagency Registry for Mechanically Assisted Cir-
culatory Support; MCS, mechanical circulatory support; NYHA,
New York Heart Association.decreased over the past decade.3,6,7 This increased risk is at
least in part related to the end-organ dysfunction associated
with cardiogenic shock and the inﬂammatory state of severe
shock, leading to increased postimplant bleeding, infection,
multisystem organ failure, and need for right heart support.
Avoidance of support is not an adequate strategy and
management algorithms in INTERMACS I patients have
evolved to use temporary MCS devices, such as intra-aortic
balloon counter-pulsation, percutaneous or surgical centrifu-
gal devices (TandemHeart, Centrimag), percutaneous axial
ﬂow devices (Impella), or venoarterial extracorporeal mem-
brane oxygenation (VA ECMO) in an effort to restore end-organ
perfusion, stabilize the patient, and potentially reduce the risk
of subsequent durable LVAD implantation.8
In general, patients with cardiogenic shock who can be
stabilized with percutaneous support may be candidates for a
durable LVAD, whereas patients who suffer from irreversible
end-organ dysfunction (renal, hepatic, neurologic, etc.) or
refractory shock despite temporary MCS are likely at higher
risk and are suboptimal candidates for LVAD implantation.
Patients who are inotropic therapy dependent (INTERMACS
levels 2 and 3) currently represent nearly two-thirds of all
LVAD implantations and likely also represent the most
appropriate use of the current technology. Patients treated
with inotropic therapy due to refractory end-organ hypoperfu-
sion or refractory symptoms related to advanced heart failure
have an overall very poor prognosis with medical therapy
alone. Of the 61 patients in the medical therapy arm of the
REMATCH trial, 72% of patients were on continuous inotropic
infusion, and by one year, only 25% of medically treated
patients were alive, which decreased to 8% by two years.2 The
Investigation of Non-Transplant Eligible Patients who are
Inotrope Dependent (INTrEPID) and Continuous Outpatient
Support with Inotropes (COSI) trials are two other small
prospective analyses, which demonstrated a 1-year survival of
11% and 6%, respectively in patients bound to continuous
inotropic therapy support.9,10 In contrast, the expected one-
year survival of patients following implantation of a continu-
ous ﬂow LVAD now approaches 80% (Fig. 1).6 Although the
patient populations in these trials differ, these data infer a
dramatic survival advantage for durable MCS in INTERMACS
levels 2 and 3 patients with advanced heart failure.
Patients in INTERMACS levels 4 through 7 suffer from
advanced heart failure but are not inotrope dependent. Not
only are patients with this severity of illness more difﬁcult to
deﬁne, it is possible for an individual patient to transition
between levels over time. Currently, only 18.5% of patients
who undergo durable MCS are levels 4 through 7 (mostly
INTERMACS level 4).6 Of these patients, the INTERMACS 4
proﬁle is increasingly gaining acceptance as an appropriate
candidate group. Such patients exhibit symptoms of dyspnea
and fatigue on minimal activity, are typically house bound
due to the severity of symptoms, and suffer from a poor
quality of life and excess 1-year mortality. The recently
concluded ROADMAP trial provides insight into the selection
of patients for LVAD therapy from this group of individuals.11
Further estimation of prognosis in this ‘‘less sick’’ patient
population is warranted with the use of other prognostic
indicators in chronic heart failure, many of which are listed
in Table 2.12–19
Fig. 1 – One-year survival of patients on continuous
inotropic support compared to those supported with a
durable continuous flow left ventricular assist device. One-
year survival was 25% in the medically treated arm of the
REMATCH trial, 72% of whom were dependent on inotropic
therapy. Survival was 11% and 6% in the prospective
analyses INTrEPID and COSI, respectively at one year. In
comparison, based on the 7th INTERMACS annual report,
the one-year survival of patients supported with a durable
continuous flow left ventricular assist device is
approximately 80%. REMATCH, Randomized Evaluation of
Mechanical Assistance for the Treatment of Congestive
Heart Failure; INTrEPID, Investigation of Non-Transplant
Eligible Patients who are Inotrope Dependent; COSI,
Continuous Outpatient Support with Inotropes.
Table 2 – Poor prognostic markers in heart failure.
 Symptoms at rest (NYHA class IV) or with minimal exertion
 Recurrent heart failure hospital admissions
 Tachycardia
 Sustained ventricular arrhythmia
 Hypotension
 Cardiac cachexia
 Hyponatremia
 Renal dysfunction
 Hepatic dysfunction
 Anemia
 Prior or current need for inotropic therapy
 High diuretic requirement (furosemide equivalent >160 mg/day)
 Circulatory or renal limitations to neurohormonal antagonists
 Nonresponder to cardiac resynchronization therapy
 Lower EF and large left ventricular volume
 Mitral regurgitation
 Pulmonary hypertension and right ventricular dysfunction
 Six-minute walk distance <300 m
 Peak VO2 < 14 mL/kg/min (not on beta blocker)
or <12 mL/kg/min (on beta blocker), or <50% of predicted
 Ve/VCO2 slope >35
NYHA, New York Heart Association; EF, ejection fraction; VO2,
oxygen consumption; Ve/VCO2, ventilatory efﬁciency (Ve, minute
ventilation; VCO2, production of carbon dioxide per minute).
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MACS registry that aims to further characterize medically
managed patients in INTERMACS levels 4–7.20 The pilot data
from the ﬁrst 166 patients enrolled in MEDAMACS demonstratea 1-year survival of 78% in INTERMACS level 6/7, a 67% 1-year
survival in INTERMACS level 5, and a 39% 1-year survival in
INTERMACS level 4. Based on this limited data, there is unlikely
to be a signiﬁcant survival advantage to LVAD implantation in
INTERMACS level 6 or 7. INTERMACS levels 4–6 patients were
analyzed prospectively in the recently reported prospective
observational ROADMAP trial, which offered all enrolled
patients implantation of a continuous ﬂow LVAD, and com-
pared those who underwent implantation to those who chose
medical therapy.11 Of the 196 patients enrolled, 95 underwent
implantation of an LVAD. By intention to treat, there was no
difference in mortality (since advancing symptoms in the
medical therapy arm resulted in transition to LVAD implant),
but showed improvements in functional capacity, quality of life,
and depression in the LVAD group.
Patients in INTERMACS levels 6 or 7 are likely too well to
beneﬁt substantially from durable MCS and implantation in
this cohort of patients with current generation devices is likely
to be too early. A decision to implant a durable MCS device in
INTERMACS 4 patients should be based on the potential beneﬁt
in functional capacity and quality of life versus the risks
(namely stroke, hemorrhage, thrombosis, and infection)
associated with durable MCS therapy. An appropriate in-
formed consent process that simpliﬁes the education regard-
ing LVAD therapy and deﬁnes these risk-beneﬁt ratios
objectively is needed to involve the patient as the principal
decision maker in such scenarios.
1.2. Understanding the role of heart failure phenotype in
decision making
Prior to consideration of LVAD implantation, the likelihood of
spontaneous recovery should be assessed. Patients who are
likely to recover and able to be stabilized on medical therapy
should not have a durable mechanical support device
implanted, and those who are likely to beneﬁt from valve
surgery or revascularization should have these attempted
prior to LVAD implantation. There is often signiﬁcant
uncertainty as to whether or not revascularization or valvular
intervention prior to LVAD will preclude the need for
mechanical support; in those cases it is prudent to evaluate
a patient fully for candidacy of LVAD therapy prior to the
proposed intervention in case of the need for a ‘‘bail out’’
strategy. Cardiac resynchronization therapy (CRT) in inotrope-
dependent patients has been associated with poor outcomes,
and therefore implanting a CRT device in patients on inotropic
therapy may only cause delays in LVAD implantation risking
further end-organ dysfunction or death.21 However, even if 1 in
3 patients were to beneﬁt substantially from CRT, it makes
prudent sense to employ this strategy as a preemptive move,
but it is imperative that the response to CRT be assessed early
with planned escalation of therapy once nonresponder status
is conﬁrmed.
Typically, patients undergoing MCS are those with a dilated
left ventricle since cannula positioning is difﬁcult in those with
smaller ventricles. Those with a restrictive or hypertrophic
cardiomyopathy pose a technical challenge related to inﬂow
cannula placement in a small ventricular cavity; however, in
those patients in whom implantation of an LVAD is technically
feasible, perioperative and one-year outcomes do not appear
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cardiomyopathy.22 Patients with a recent myocardial infarc-
tion involving the left ventricular apex theoretically have an
increased surgical risk. Certain valvular pathologies may need
to be addressed at the time of MCS implantation and should be
fully evaluated prior to surgery. Typically, while supported
with a continuous ﬂow LVAD, the aortic valve opens
infrequently and may be at increased risk for thrombosis;
therefore, mechanical aortic prostheses are often replaced
with a bioprosthetic valve. Aortic regurgitation often worsens
following continuous ﬂow LVAD implantation, which
decreases pump efﬁciency by recirculation, imposing an
increased volume load on the left ventricle. Therefore, patients
with moderate or severe aortic regurgitation often undergo
concurrent closure, oversewing, or replacement of the aortic
valve.23 Mitral regurgitation improves in most of the patients
following LVAD implantation when it is functionally related to
left ventricular dilation and volume, and does not often
require surgical intervention; conversely, signiﬁcant mitral
stenosis limits LVAD ﬁlling and requires replacement of the
stenotic mitral valve with a bioprosthesis.24 Atrial septal
defects and patent foramen ovale should be identiﬁed prior to
surgery and should be closed at the time of LVAD implantation
given the decrease in left atrial pressure following LVAD
implantation and the possibility of postoperative right to left
shunt, facilitated by residual right ventricular failure.
1.3. Assessment of the right ventricle
Ongoing right ventricular dysfunction following isolated left
ventricular mechanical support may pose a persistent limita-
tion to functional capacity and impair end-organ function.
Right ventricular failure following LVAD implantation
increases the risk of death and may necessitate the implanta-
tion of a right ventricular mechanical support device or use of
prolonged continuous intravenous inotropic therapy. In the
current era, right ventricular mechanical support is only
available to those patients who are listed for cardiac
transplantation (since discharge to home is often difﬁcult),
thereby placing profound importance in identifying those at
risk for postoperative right ventricular failure, especially in
patients not eligible for cardiac transplantation.
LVAD implantation may not only unmask preexisting right
ventricular dysfunction, but several factors associated with
left ventricular MCS may further impact right ventricular
performance. Ischemic injury associated with cardiopulmo-
nary bypass may at least temporarily worsen right ventricular
function. Increased systemic venous return with left ventric-
ular mechanical support causes an increase in preload to the
right ventricle, which in concert with a reduction of left
ventricular pressure due to direct unloading may shift the
septum toward the left ventricle causing worsening right
ventricular dilation and tricuspid regurgitation and decreased
septal contribution to right ventricular forward output.25
Assessment of right ventricular function should incorpo-
rate a combination of imaging ﬁndings (to assess RV
contractility and diastolic compliance) with hemodynamic
(to assess systemic elevation of ﬁlling pressures and contrac-
tile insufﬁciency) and biochemical data (to assess hepatorenal
end-organ perfusion). Preoperative severe right ventriculardysfunction by qualitative and quantitative echocardiographic
evaluation, inability to decrease the right atrial pressure to
below 15 mmHg with optimal medical therapy, a low right
ventricular stroke work index, low right atrial to pulmonary
artery pulse pressure ratio, high right atrial to pulmonary
artery wedge pressure ratio, and persistent elevations in
creatinine, bilirubin, and international normalized ratio (INR)
all indicate an increased risk for postoperative right ventricu-
lar failure.25 No single factor has been shown to be adequate in
the prediction of right ventricular failure; therefore, during the
evaluation of a patient referred for left ventricular mechanical
support, all of these factors should be comprehensively
examined.
In addition to assessing right ventricular function, special
attention should be directed toward the arrhythmia burden.
Signiﬁcant ventricular arrhythmias may result in a hemody-
namic embarrassment in patients with isolated left ventricu-
lar mechanical support; therefore, strong consideration should
be given to biventricular MCS in patients with very frequent or
refractory ventricular arrhythmia.
1.4. Estimating the impact of comorbid conditions
Data regarding the impact of advanced age on LVAD
outcomes are variable. A single center reported outcomes
of 30 patients over the age of 70 with a 97% 30-day and 70%
two-year survival following LVAD implantation, which was
not different from patients at the same institution undergo-
ing LVAD implantation at an age less than 70 years old.26 This
is contrary to the seventh INTERMACS registry report, which
revealed an increased perioperative and late mortality in
older patients.6
Given the hemorrhagic and thrombotic complications,
which are unfortunately common following LVAD implanta-
tion, patients with hypercoagulable disorders or coagulopa-
thies should be considered at increased risk for postoperative
complications. All patients who undergo LVAD implantation
must be able to tolerate systemic anticoagulation, which at the
current time consists of warfarin with an INR of 2.0–3.0 and
aspirin (or an alternate antiplatelet agent).25
Renal and hepatic dysfunction are associated with an
increase in perioperative mortality, the risk of which relates to
the degree of impairment. These two end organs typically
predict underlying chronicity of the disease, a worse right
heart function, and predispose to a greater propensity for
bleeding and infection-related complications. Despite this
association, on average, both renal and hepatic function
improve by six months following LVAD implantation.27
Patients on hemodialysis have an overall poor prognosis
and are likely at increased risk of device infection and most
centers consider LVAD implantation in this population
unattractive. In patients with marginal renal function,
improvement with a trial of inotropic therapy and lack of
signiﬁcant proteinuria may suggest a greater likelihood of
renal recovery following LVAD implantation. Chronic eleva-
tion in right atrial pressure resulting in longstanding hepatic
congestion may ultimately lead to hepatic cirrhosis. Patients
with chemistry or imaging data indicating the possibility for
cirrhosis (or even extensive hepatic ﬁbrosis) should undergo
liver biopsy, as patients with cirrhosis are suboptimal
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operative bleeding and perioperative mortality, especially
those who are Childs-Pugh class B or C or have an elevated
Model for End-Stage Liver Disease (MELD) score.28
The presence of peripheral arterial disease at the time of
LVAD implantation may increase the risk of stroke, and limb
and mesenteric ischemia; this depends largely on the extent of
vascular disease, and in some cases, this may be considered a
relative contraindication to durable LVAD implantation. In
addition, signiﬁcant disease of the ascending aorta may
contraindicate the anastomosis of the outﬂow graft, necessi-
tating alternative connections, such as in the descending
aorta, in some cases.
Psychosocial barriers including inadequate social support,
substance abuse, and medical noncompliance all should be
assessed prior to consideration of LVAD therapy. Poor
nutritional status and frailty increase the risk of death
following LVAD implantation, although no method of improv-
ing these parameters to mitigate this risk has been demon-
strated.29 Frailty is increasingly recognized as a risk marker for
poor outcome and should be evaluated independent of the
patient's age. A simple 6-second ‘‘shuttle’’ test to see if the
patient can walk 5 meters and assessment of hand grip
strength (<20th percentile for age and gender) can be used to
establish frailty.29,30 Another important consideration is in the
neuropsychological evaluation of cognitive function; recent
studies have shown that cognitive function, which is often
poor in advanced heart failure, improves signiﬁcantly after
LVAD implantation. However, advanced cognitive decline may
be a harbinger for poor adherence to the medical regimen and
complicate LVAD management.31
2. Outcomes following LVAD implantation
2.1. Survival
Based on data from the INTERMACS registry, perioperative (30-
day) survival is 95% following LVAD implantation.32 Survival
following LVAD implantation has improved as device technol-
ogy and patient selection have advanced. One-year survival
following LVAD implantation for transplant ineligible candi-
dates was 53% in the pulsatile HeartMate XVE arm of the
REMATCH trial; most recently, the INTERMACS registry data
from the years 2008 to 2014 demonstrated a 1-year survival of
80% and median survival of nearly four years for patients
supported with a continuous ﬂow LVAD. The greatest risk of
death following LVAD implantation is in the early postopera-
tive period and reaches a nadir by 3 months postoperatively.
Factors that have the greatest impact on perioperative
mortality include age, female sex, prior stroke, mechanical
ventilation, INTERMACS level 1 or 2, LVAD for destination
therapy, hepatic or renal dysfunction, right ventricular
dysfunction or need for right ventricular mechanical support,
and prior or other concurrent cardiac surgery.3,6
2.2. Quality of Life
The impact of LVADs on symptom burden and quality of life in
patients with severe heart failure has been favorable.6 In theHeartMate II destination therapy trial, all patients experienced
NYHA class III or IV heart failure symptoms at the start of the
trial, and by the end, 80% of those undergoing support with a
continuous ﬂow LVAD were NYHA class I or II.33 In addition,
patients in this trial demonstrated meaningful improvements
in the Minnesota Living with Heart Failure questionnaire and
Kansas City Cardiomyopathy questionnaire, with a signiﬁcant
increase in a 6-min walk distance by 12 months. This should be
tempered by the understanding that complications following
LVAD implantation are often unrelated to heart failure, and
therefore, heart failure speciﬁc quality of life assessments may
overestimate the beneﬁt of LVAD therapy.
2.3. Complications following LVAD
The most common complications in patients supported with
an LVAD are bleeding, LVAD thrombosis, stroke or systemic
thromboembolism, and infection.
Following the 30-day perioperative period, bleeding (mostly
gastrointestinal) occurs at a rate of 8–23% by one year.34
Several factors place patients with continuous ﬂow LVADs at
risk for gastrointestinal bleeding. Background antithrombotic
therapy with warfarin and an antiplatelet agent (usually
aspirin) increase the overall bleeding risk. Shear stress from
the pump itself may lead to platelet dysfunction and
degradation of large von Willebrand factor multimers in the
setting of low pulsatility leads to further coagulopathy.35
Gastrointestinal arteriovenous malformations are common
and difﬁcult to treat lesions in patients with LVADs and are
likely related to the reduced arterial pulsatility related to
continuous ﬂow support; this phenomenon is similar to
Heyde's syndrome, which was initially described in calciﬁc
aortic stenosis.35 The effects of low pulsatility on the
microcirculation, coupled with increased oxidative stress,
are the most likely mechanistic candidates that predispose to
development of this unique gastrointestinal complication, in
concert with the hematological abnormality encountered
universally with continuous ﬂow LVADs.
Pump thrombosis occurs with an annual incidence of 6–
12% and is associated with an increase in neurologic events
and a higher rate of mortality.36–38 LVAD thrombosis is often
initially suspected when there is biochemical evidence of
hemolysis caused by turbulent VAD ﬂow or elevation in the
device power; later, signs include an inability to unload the left
ventricle as determined by noninvasive imaging or invasive
hemodynamic study, decompensated heart failure, and
possibly hemodynamic compromise.39 Lactate dehydrogenase
(LDH) has proven to be an excellent biomarker of hemolysis
and hence impending or established pump thrombosis.
Elevation of LDH often precedes pump thrombosis by several
weeks, and is therefore often monitored as routine surveil-
lance for LVAD thrombosis in an effort to initiate intensiﬁed
therapy to prevent surgical pump exchange, although this
strategy may be fraught with peril.36 From the time of
conﬁrmed pump thrombosis, there is a two-fold increase in
mortality at 30 days, 90 days, and 6 months.37 Patients who
have suspected LVAD thrombosis and do not undergo LVAD
exchange or cardiac transplantation have a 6-month mortality
of 48.2% inferring that medical therapy for VAD thrombosis
may be inadequate or cause harm (as in the case of
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est 6.5% perioperative mortality risk and a 65% 2-year survival
following exchange.40
Infection is common and occurs in about 20% of patients
following LVAD implantation, which may manifest as sepsis or
a driveline infection.34 Infection associated with LVAD therapy
should be treated aggressively and may require long-term
suppressive antibiotics unless the device is exchanged or the
patient undergoes cardiac transplantation. Infection and its
inﬂammatory sequelae predispose to a prothrombotic milieu,
as well as heighten the risk of neurological complications.
Cerebrovascular complications, especially strokes, remain
an Achilles heel of LVAD implants, with an annual incidence
exceeding 6%. This complication is certainly more common
with certain devices such as the HVAD (HeartWare, Framing-
ham, MA) which exhibitis an excessively high rate of stroke at
2 years (29%), in women, and in those with a pre-implant
history of stroke or atrial ﬁbrillation. A complex weave of
stroke-related events in the setting of infection or with pump
thrombosis has been observed. Unless this complication is
reduced with newer devices or enhanced management
strategies, adoption of LVADs to less sicker patients will
remain limited since the occurrence of a disabling stroke is
tantamount to a less meaningful survival beneﬁt.41
In aggregate, by one year, 80% of patients undergoing LVAD
implantation will be alive and on average will have an
improved quality of life. Fifty-ﬁve percent will be rehospita-
lized for any cause, 30% will have major bleeding within the
ﬁrst month, and 20% will have major bleeding over the
following 11 months. Ten percent of patients will have a
stroke, 5% will have a device malfunction related to clotting,
20% will have a serious infection, and 18% will have ongoing
heart failure.34 These summary statistics are a reasonable way
of developing a well-crafted informed consent process for
patients and their caregivers to help them understand the
expectations post implantation.
3. Summary
The application of LVAD therapy continues to evolve with
technological advances on the background of a limited donor
supply and a growing population of patients with advanced
heart failure. The ideal patients for durable LVAD implantation
either as a bridge to transplantation or as destination (lifetime)
therapy are those requiring continuous inotropic support
(INTERMACS 2, 3) or nearing the need for such therapy
(INTERMACS 4). This cohort of patients should be stable
enough to undergo an operation safely and continued medical
therapy is associated with a poor prognosis (<50% 1-year
survival). Patients in cardiogenic shock who ultimately
undergo durable LVAD implantation have a median survival
of three and a half years, and therefore should be considered
candidates for durable mechanical support ideally following a
period of temporary mechanical support to improve end-organ
function and potentially reduce perioperative risk.
Despite the success of the contemporary devices in
providing circulatory support, the bane of complications limits
the expansion of this therapy and will need to be overcome
with future device iterations. The HeartMate III is a newpromising centrifugal pump currently in trial (MOMENTUM
III), which aims to reduce complications by addressing some of
the pathophysiologic mechanisms thought to be responsible
for bleeding and thrombosis associated with current genera-
tion devices.42 The HeartMate III LVAD features an automated
speed variability at 30 cycles per minute, which produces ﬂow
pulsatility, large blood ﬂow gaps to reduce hemolysis, and
textured surfaces, which are meant to improve hemocompat-
ibility. As device technology continues to advance, LVADs will
inevitably move beyond an option only for select patients and
will migrate toward a broader population of less sick heart
failure patients. Pushing technology forward will likely need to
be coupled with a reduction in complications and a better
understanding of the cost-effectiveness and ﬁnancial impact
of this transformative therapy.
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